Recombinant humanized antivascular endothelial growth factor (rhuMAbVEGF) is a monoclonal IgG, antibody that is being developed as an antiangiogenic agent for use in treating a variety of solid tumors. Preclinical safety studies included an immunohistochemical tissue cross-reactivity study, in vitro hemolytic potential and blood compatibility studies, and multiple dose toxicity studies. Toxicity studies were conducted in cynomolgus monkey because rhuMAbVEGF is pharmacologically active in this species and does not bind rat or mouse vascular endothelial growth factor (VEGF). Following twice weekly administration of rhuMAbVEGF for 4 or 13 wk, young adult cynomolgus monkeys exhibited physeal dysplasia characterized by a dose-related increase in hypertrophied chondrocytes, subchondral bony plate formation, and inhibition of vascular invasion of the growth plate. In addition, decreased ovarian and uterine weights and an absence of corpora lutea were observed in females receiving 10 and 50 mg/kg/dose in the 13-wk study. Both the physeal and ovarian changes were reversible with cessation of treatment. No other treatment-related effects were observed following rhuMAbVEGF administration at doses up to 50 mg/kg. These findings indicate that VEGF is required for longitudinal bone growth and corpora lutea formation and that rhuMAbVEGF can reversibly inhibit physiologic neovascularization at these sites.
INTRODUCTION
Recombinant humanized antivascular endothelial growth factor (rhuMAbVEGF) is a recombinant humanized IgGi monoclonal antibody against vascular endothelial cell growth factor (VEGF); rhuMAbVEGF is being developed as an antiangiogenic agent for the treatment of solid tumors. While angiogenesis plays a role in physiologic processes such as embryogenesis, wound healing, and corpus luteum formation, angiogenesis has also been implicated in the pathogenesis of a variety of disorders, including the growth and metastasis of solid tumors, intraocular neovascularization, rheumatoid arthritis, and psoriasis (17, 21, 28, 29, 43, 45) . A number of factors have been implicated in the control of angiogenesis (28, 30, 43, 49, 69) , and identification of potential mediators of physiologic and/or pathologic angiogenesis is an active area of research.
VEGF is a secreted, endothelial-specific mitogen and angiogenic factor that also has profound effects on vascular permeability, as it is 50,000 times more potent than histamine (25, 46, 65) . VEGF is encoded by a single gene, but alternative splicing of VEGF mRNA produces 4 different secreted isoforms (121, 165, 189, and 206 amino acids) that are characterized by an increasing affinity for heparin and an ability to bind cell-surface and matrix heparan sulfate proteoglycans (31, 32, 46, 58) . VEGF exists as a homodimer of 2 identical disulfidelinked subunits (25) , and it exerts its effects on the vasculature through KDR and Fltl, 2 high-affinity tyrosinekinase receptors, whose constitutive expression is restricted to endothelial cells (16, 35, 53, 59, 71, 74) . VEGF mRNA is expressed in a wide variety of normal adult and fetal tissues, including those of the lung, kidney, liver, adrenal gland, heart, aorta, ovary, uterus, and placenta (7, 12, 27, 35, 36, 38, 56, 62, 67, 72) ; the concomitant expression of KDR and Fltl on adjacent endothelial cells in these tissues suggests that VEGF paracrine signaling may be important in vascular maintenance (in addition to its role in angiogenesis). have demonstrated that VEGF plays a pivotal role in both physiologic and pathologic angiogenesis. VEGF is absolutely required for normal fetal development, since the loss of even a single VEGF allele results in embryonic lethality (13, 22) . VEGF also appears to be critical for the normal postnatal maturation of specific organs, such as the kidney, since administration of a polyclonal neutralizing anti-VEGF antibody to neonatal mice results in systemic edema, loss of glomerular capillary tufts, and death (42) . VEGF may also be important in tumor angiogenesis, since VEGF mRNA is expressed in a wide variety of human tumors (6, 7, 9-11, 18, 50, 59, 68) and is upregulated by local hypoxia (41, 55, 68) , which is frequently present in poorly perfused tumors. In addition, VEGF concentrations in ocular fluids are highly correlated with active proliferation of blood vessels in patients with diabetic and other ischemia-related retinopathies (2) , and VEGF has been localized in choroidal neovascular membranes of patients with age-related macular degeneration (48) .
The murine antihuman IgG ¡ monoclonal antibody muMAbVEGFA4.6.1 (A4.6.1) (40) has been used extensively to test the hypothesis that VEGF is a mediator of pathologic angiogenesis in vivo. This high-affinity antibody, which recognizes all 4 VEGF isoforms (40) , has been shown to potently suppress both the growth rate and the weight of several different human tumor cell lines that have been transplanted into nude mice (8, 24, 41, 52, 75) . This decrease in tumor size was accompanied by a decrease in the number of CD31-positive vessels (Ryan and Hagler, unpublished data), demonstrating that the antibody acts by inhibiting tumor angiogenesis rather than by directly affecting tumor cells. Inhibition of tumor growth and the decrease in tumor vascular density was not complete, however, since A4.6.1 neutralizes only the human VEGF produced by the tumor xenograft; A4.6.1 I does not inhibit endogenous murine VEGF, which is still available for receptor binding. Intraocular administration of A4.6.1 has also been shown to inhibit iris neovascularization in a primate model of ischemic retinal disease (1) .
Inhibition of pathologic angiogenesis in these models indicates that therapeutic strategies directed at inhibiting VEGF-mediated angiogenesis may be useful in the treatment of solid tumors or ocular neovascularization. However, a major limitation in using murine antibodies as a therapeutic in humans is the development of an antiantibody response (54, 64) . Even chimeric antibodies (where the variable domains of rodent antibodies are fused to human constant regions) can elicit a significant immune response (57) . To overcome this limitation, murine monoclonal antibodies can be &dquo;humanized&dquo; (37, 63) . A4.6.1 was humanized by transferring the critical epitope-binding regions of A4.6.1 to the same human IgG¡ framework used in other monoclonal antibody therapeutics (14, 19, 20, 61) . The humanized antibody, rhu-MAbVEGF, inhibited VEGF-induced proliferation of endothelial cells for both in vitro and in vivo tumor growth with a potency and efficacy similar to that of A4.6.1 (60) . rhuMAbVEGF is currently undergoing human clinical trials, in which it is being utilized as an antiangiogenic agent in the treatment of solid tumors.
In addition to its expression at sites of angiogenesis, the widespread expression of VEGF in numerous tissues with essentially quiescent endothelia suggests that this growth factor may play an additional role in the maintenance of existing vasculature. Since neither A4.6.1 nor rhuMAbVEGF neutralized endogenous murine VEGF in the murine tumor efficacy models, it was not known whether inhibition of constitutively expressed VEGF would disrupt existing endothelial cells or alter vascular permeability until safety studies were initiated in primates. In addition to supporting the proposed clinical plan for multiple intravenous administration in humans, the preclinical safety program for rhuMAbVEGF was designed to capture changes in endothelial cell integrity or function, changes that could not be detected in heterologous species such as mouse or rat. Prior to entry into man, the safety assessment for rhuMAbVEGF consisted of an immunohistochemical tissue cross-reactivity study, in vitro hemolytic potential and blood compatibility studies, and 4-and 13-wk multiple-dose toxicity studies with a 4-wk recovery period in young adult cynomolgus monkeys.
PRECLINICAL SAFETY EVALUATION OF RHUMABVEGF Tissue Cross-Reactivity Study
In order to determine whether rhuMAbVEGF exhibited unexpected tissue cross-reactivity or non-target tissue binding, fresh frozen normal adult human, cynomolgus monkey, and rabbit tissues were screened by immunohistochemistry. The recommended panel of tissues (15) , consisting of surgical samples from unrelated human donors and primate and rabbit tissues collected at necropsy (n = 3/species), were screened by routine immunohistochemical procedures using biotinylated rhu-MAbVEGF, at concentrations of 10 and 400 )JLg/ml, as the primary antibody. (The latter concentration represented the approximate maximum blood concentration of rhuMAbVEGF expected after a potential high dose of 10 mg/kg in humans.) E25, an unrelated humanized monoclonal antibody on the same IgG, framework (61), was used as the isotype control. VEGF-loaded microspheres injected subcutaneously and uninjected skin were included as positive and negative tissue controls in each staining run. No tissue cross-reactivity or non-target tissue binding was observed with rhuMAbVEGF at 10 or 400 ,g/ml in any of the tissues or species screened.
In Vitro Hemolytic Potential and Blood Compatibility Studies
In these studies, the hemolytic potential of rhu-MAbVEGF for whole blood and its compatibility with serum and plasma were determined prior to intravenous administration in primates. Hemolytic potential was assessed by mixing equal volumes of rhuMAbVEGF (or vehicle) and human or cynomolgus monkey heparinized whole blood (final concentration of rhuMAbVEGF = 5 mg/ml). Following incubation at 38°C for 40 min, the concentration of hemoglobin in the supernatant plasma was determined spectrophotometrically. As a positive control, saponin ( 1 %) was used to induce hemolysis of erythrocytes.
The compatibility of rhuMAbVEGF with serum or plasma was scored by the absence of precipitation or coagulation in a mixture of equal volumes of rhuMAb-VEGF (or vehicle) and human or cynomolgus monkey serum or plasma (final concentration of rhuMAbVEGF = 5 mg/ml) following incubation at room temperature (22°C) for 25 min.
At concentrations up to 5 mg/ml, rhuMAbVEGF did not cause hemolysis of human or cynomolgus monkey erythrocytes, and it was compatible with both human and cynomolgus monkey serum and plasma.
Multiple-Dose Toxicity Studies
These studies were performed to determine the toxicity of rhuMAbVEGF following twice-weekly bolus intravenous administration for 4 or 13 wk and to determine the reversibility, persistence, or delayed occurrence of toxic effects following a 4-wk recovery period. Because rhuMAbVEGF does not bind rodent VEGF, it would not be active in these species; therefore, the multiple-dose toxicity studies were only conducted in primates. Cynomolgus monkeys were chosen because cynomolgus monkey VEGF cDNA is 99% homologous to human VEGF (66) and because rhuMAbVEGF had been shown to be pharmacologically active in a cynomolgus model of iris neovascularization (1) .
For each study, young adult to adult male and female cynomolgus monkeys (2.2-3.6 kg) were assigned at random to 4 treatment groups. Animals were administered rhuMAbVEGF twice weekly for 4 or 13 wk (via bolus intravenous injection into the saphenous vein) at 0 (vehicle control), 2, 10, and 50 mg/kg/dose (4 animals/sex/ group). These doses were selected because they represented the approximation of and significant multiples beyond the highest intended clinical dose on a body weight basis (mg/kg). In both the 4and 13-wk studies, an additional 2 males and 2 females were included in the vehicle and 50 mg/kg/dose groups as the 4-wk recovery groups.
In-life evaluations included the following: twice-daily clinical observations (am and pm), weekly body weight measurements, daily qualitative food consumption measurements, blood pressure measurements, electrocardiograms, physical exams (including rectal temperatures and respiration rates), ophthalmic exams (including electroretinograms), and clinical pathology (hematology, clinical chemistry, and urinalysis). Blood samples were collected for serum drug concentrations and for measurement of antibodies against rhuMAbVEGE At the end of the 4or 13-wk dosing period (terminal necropsy) or following the 4-wk recovery period (recovery necropsy), animals were anesthetized, exsanguinated, and necropsied. Macroscopic and microscopic examinations of tissues and injection sites were performed on each animal. In addition to routine carcass and organ weight measurements, organ-tobody weight percentages, and organ-to-brain weight ratios, wet-to-dry weight ratios were determined for kidney, liver, lung, and skeletal muscle in order to specifically rule out changes in vascular permeability (4-wk study only). Bone marrow smears were prepared to quantitate myeloid-to-erythroid ratios, and sections of kidney and eye were preserved for possible electron microscopy and immunohistologic examination.
All animals survived to their respective scheduled necropsy. No test material-related clinical signs of toxicity were observed in terminal or recovery necropsy animals following either the 4or 13-wk dosing periods. In addition, rhuMAbVEGF had no effect on body weight, cumulative body weight gain, food consumption, blood pressure measurements, electrocardiograms, physical examination measurements, ophthalmic findings, or electroretinography in either study. In addition, there were no effects on any hematology, bone marrow, clinical chemistry, or urinalysis parameters after 4 or 13 wk of treatment with rhuMAbVEGF Pharmacokinetic analyses demonstrated a dose-proportional increase in the measured concentrations of rhu-MAbVEGF ; clearance and half-lives were comparable to those determined following single intravenous dose administration (data not shown). No anti-rhuMAbVEGF antibodies were detected in animals receiving rhuMAb-VEGF, even after 13 wk of treatment.
There were no macroscopic or organ weight changes related to the administration of rhuMAbVEGF, other than decreases in ovarian and uterine weights in mid-and high-dose females in the 13-wk study (see below). Changes in wet-to-dry organ weight ratios, which suggest effects on vascular permeability, were not observed after 4 wk of rhuMAbVEGF administration.
Microscopic changes following administration of rhuMAbVEGF were confined to the growth plates in the 4-and 13-wk studies and to ovaries in the 13-wk study.
Treatment-related vascular endothelial damage, hemorrhage, or edema were not observed in any organ, and there was no evidence of local irritation associated with test material administration at the injection sites.
Growth Plates. Physeal dysplasia of the appendicular growth plates was observed in animals that received rhuMAbVEGF for 4 or 13 wk. (Only the distal femoral physis was examined during the 4-wk study; in the subsequent 13-wk study, proximal and distal femoral and humeral growth plates were examined, and bilaterally symmetrical physeal dysplasia was observed at all sites.) The physeal dysplasia was characterized by markedly thickened growth plate cartilage; degeneration of cartilage matrix; disorganization of chondrocyte columns, which formed packets or clusters; decreased numbers of primary bony trabeculae with inappropriate retention of hypertrophied chondrocytes in trabeculae; absence of metaphyseal capillary invasion into the zone of hypertrophied chondrocytes; and formation of a transverse subchondral bony plate ( Fig. lA-F) .
The incidence of the physeal dysplasia was related to the dose and duration of treatment (Table I) and was only partially resolved with the resumption of capillary invasion into the growth plate following a 4-wk recovery period ( Fig. 1G-I ). This suggests that while rhuMAbVEGFmediated inhibition of capillary invasion of the growth plate is a reversible event, complete resolution of the as- 50 mg/kg/dose rhuMAbVEGF at terminal necropsy; (G-1) 50 mg/kg/dose rhuMAbVEGF following a 4-wk recovery period. Physeal dysplasia was characterized by a 3-4-fold increased thickening of growth plate cartilage (D); degeneration of the cartilage matrix (E); disorganization of the chondrocyte columns, which formed packets or clusters (E, H); decreased numbers of primary bony trabeculae with inappropriate retention of hypertrophied chondrocytes in trabeculae (E, H); absence of metaphyseal capillary invasion into the zone of hypertrophied chondrocytes (F); and formation of a transverse subchondral bony plate (F). Physeal dysplasia was only partially resolved by the resumption of capillary invasion into the chondrocyte columns in the recovery necropsy animals (G-1), indicating that inhibition of capillary invasion of the growth plate is a reversible event but that complete resolution of the growth plate thickening takes longer than 4 wk. Similar changes were seen in both sexes in the 13-wk study, although females were generally less severely affected because of their greater skeletal maturity. Magnifications: (A, D, E) X 12.5; (B, E, H) x63; (C, F, I) X 158. sociated physeal dysplasia required more than the 4-wk recovery period.
There was a trend toward a dose-dependent increase in the severity of physeal dysplasia in males; the severity was minimal to slight in 3 of 4 animals in the 2-mg/kg/ dose group and moderate to severe in the other male (13- wk only) and in all animals in the 10-and 50-mg/kg/dose groups (both studies). In contrast, both the incidence and severity of physeal dysplasia was decreased in females relative to males; this sex bias toward males was attributed to differences in sexual maturity rather than to a direct sex effect. Based upon testicular histology, the males were considered sexually immature; consequently, their open growth plates would be more susceptible to the antiangiogenic effects of rhuMAbVEGF In contrast, the females of similar size and weight were more sexually Changes in Female Reproductive Organs.Ovarian and uterine weights were significantly decreased in females given 10 and 50 mg/kg/dose rhuMAbVEGF for 13 wk. (Relative to vehicle controls, ovary/body weight and uterus/body weight ratios were decreased 33-46% and 28-38%, respectively.) Similar changes in female reproductive organ weights were not observed during the 4-wk study. Microscopically, decreased ovarian weights were associated with the absence of corpora lutea in 2 of 4 (10-mg/kg/dose) or 4 of 4 (50-mg/kg/dose) females, but microscopic correlates were not observed in the uterus to account for the decreased uterine weights. Following a 4wk recovery period, corpora lutea were observed in 1 of 2 females in the 50-mg/kg/dose group, and ovarian and uterine weights were similar to those of the vehicle controls, suggesting that the effects of rhuMAbVEGF on female reproductive organs were reversible following cessation of rhuMAbVEGF treatment.
DISCUSSION
rhuMAbVEGF is a monoclonal antibody against VEGF that is currently undergoing human clinical trials to investigate its use as an antiangiogenic agent for a variety of oncology indications. Previous murine in vivo efficacy studies (8, 41, 75) have shown that administration of rhuMAbVEGF decreased the growth rate, tumor size, and vascularity of human tumor xenografts in nude mice. Although VEGF is expressed in a wide variety of normal adult and fetal tissues (7, 12, 26, 35, 36, 38, 56, 62, 67, 72) , it was not possible to assess the safety of rhuMAbVEGF on any non-tumor tissues in these efficacy studies, because rhuMAbVEGF does not bind the endogenous murine VEGE Therefore, studies to identify toxicologic or histopathologic effects of rhuMAbVEGF administration, including the consequences of inhibition of VEGF paracrine signaling on the integrity of quiescent endothelia, were restricted to primates. Cynomolgus monkey was chosen as the test species because cynomolgus VEGF cDNA is 99% homologous to human VEGF (66) and because rhuMAbVEGF is pharmacologically active in this species (1) .
Prior to entry into man, several preclinical studies were conducted to assess the safety of rhuMAbVEGR Human, cynomolgus monkey, and rabbit tissue screens did not identify any unexpected tissue cross-reactivity or nontarget tissue binding. In addition, rhuMAbVEGF was compatible with human and cynomolgus monkey serum and plasma and did not induce hemolysis in vitro. Multiple-dose toxicity studies in cynomolgus monkeys demonstrated that twice-weekly intravenous bolus administration of rhuMAbVEGF for 4 or 13 wk was well tolerated and induced no clinical signs of toxicity at doses up to 50 mg/kg/dose. Clinical pathology parameters were unchanged, and no antirhuMAbVEGF antibodies were detected.
Histopathologic findings associated with rhuMAb-VEGF administration were restricted to physeal dysplasia in both studies at 2 (13-wk only), 10, and 50 mg/kg/dose rhuMAbVEGF and to the absence of ovarian corpora lutea following 13 wk of rhuMAbVEGF at 10 or 50 mg/ kg/dose. The absence of corpora lutea in the 13-wk study was associated with significantly decreased ovarian and uterine weights, but changes in other organs were not present in either study. Wet-to-dry organ weight ratios of selected organs in the 4-wk study were unchanged following rhuMAbVEGF administration, consistent with the absence of microscopic evidence of tissue edema. In addition, there was no evidence of endothelial damage, vascular hemorrhage or necrosis, or tissue ischemia-no evidence to suggest that rhuMAbVEGF altered the integrity of preexisting blood vessels.
Physeal dysplasia, characterized by thickening and disorganization of chondrocyte columns, matrix degeneration and fissures, absence of metaphyseal vascular invasion into the chondrocyte columns, and development of a subchondral bony plate, was observed in both sexes, although both the incidence and severity of the dysplasia were greater in males. This difference was attributed to differences in sexual maturity, since the animals were selected for study on the basis of weight (2.2-3.6 kg), and age-matched male cynomolgus monkeys are generally larger than females. Histologic immaturity of the testes was correlated with the presence of open growth plates, consistent with the known effects of sex hormones on growth plate closure (39) .
Longitudinal bone growth occurs at the physis and is characterized by an orderly sequence of chondrocyte differentiation through distinct zones of resting, proliferating, and hypertrophied chondrocytes ( Fig. 2A) . Proliferation of chondrocytes in the proximal portion of the physis is balanced by metaphyseal vascular invasion of the terminal hypertrophied chondrocytes and subsequent matrix mineralization, resulting in a net lengthening of the bone, while the normal thickness of the growth plate is Chondrocytes are organized into columns and pass through morphologically distinct zones (reserve, resting, proliferation, transition, and hypertrophic) as they mature. The width of the growth plate is maintained by proliferation of chondrocytes in the proliferative zone, balanced by loss of terminally differentiated hypertrophied chondrocytes via the invasion of metaphyseal capillaries in the hypertrophied zone. (B) VEGF mRNA is expressed in terminally differentiated hypertrophied chondrocytes, as shown in this section of human fetal femur (courtesy of K. Hillan). Magnification: X 158. maintained (34) . A number of angiogenic factors, including a variety of heparin-binding growth factors, have been identified in chondrocytes from the hypertrophied zone (3, 4, 44, 47, 51, 70) , and they may stimulate vascular invasion of the physis in vivo (Fig. 2B ). Experimental physical disruption of the metaphyseal blood supply results in a dramatic increase in width of the physis as a result of continued chondrocyte proliferation (73) ; this is similar to what we observed with rhuMAbVEGF in this study.
The development of corpora lutea is associated with the proliferation of vessels in the theca intema; these vessels invade the ruptured follicle to form a rich capillary network around luteal cells (5) . VEGF expression is temporally and spatially related to cyclic angiogenesis in the ovary (38, 49, 62) . VEGF has recently been shown to be required for the development of corpora lutea, since inhibition of VEGF by administration of the soluble murine VEGF receptor Flt-1-IgG inhibited corpora lutea formation in a rat model of hormonally induced ovulation (23) .
In terms of pathogenesis, we hypothesize that both the physeal dysplasia and absence of ovarian corpora lutea observed following rhuMAbVEGF administration are a direct effect of local inhibition of VEGF action at sites of active angiogenesis. rhuMAbVEGF neutralizes VEGF secreted by hypertrophied chondrocytes and ovarian luteal cells, inhibiting VEGF-mediated paracrine signaling and preventing the subsequent vascular invasion of the growth plate or follicle. Continued proliferation of chondrocytes in the absence of vascular invasion results in a markedly thickened growth plate. Limited oxygen diffusion, inadequate delivery of humoral factors that regulate chondrocyte synthetic activity, or mechanical factors related to increased thickness of the growth plate result in matrix degeneration, fissuring, and the subsequent disorganization of chondrocyte architecture. The development of the transverse bony plate may act to stabilize the physis, thereby compensating for the matrix degeneration.
Since both the growth plate and ovary are known to be sites of profound physiologic angiogenesis (in the rat, vascular ingrowth in the physis proceeds at 0.3 mm/day) (33) , the physeal dysplasia and inhibition of corpora lutea formation were consistent with the known biological activity of rhuMAbVEGF and were therefore not considered to be adverse effects. Inhibition of angiogenesis was reversible, as shown by the resumption of angiogenesis in the physis and by corpora lutea formation in recovery animals, although repair was still incomplete following the 4-wk recovery period.
CONCLUSIONS
Administration of rhuMAbVEGF to young adult, healthy cynomolgus monkeys for 4 or 13 wk demonstrated that this molecule was a well-tolerated and potent antiangiogenic agent. Clinical or pathologic changes indicative of systemic toxicity and adverse effects on existing, quiescent endothelia were not observed. The marked inhibition of physiologic angiogenesis observed in the growth plate and ovary of cynomolgus monkeys demonstrates that rhuMAbVEGF is a potent antiangiogenic agent and that VEGF is required for normal longitudinal bone growth and corpora lutea formation in primates.
